Thought Leadership
Email Page
Can the FDA Salvage Interchangeable Follow-On Biologics?
November 19, 2019
Ted Mathias, Stacie Ropka, and Michelle Divelbiss
BioProcess Online / Biosimilar Development

BioProcess Online and Biosimilar Development published "Can the FDA Salvage Interchangeable Follow-On Biologics?", an article written by Axinn partners Ted Mathias and Stacie Ropka and associate Michelle Divelbiss.

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.